{"schema_version":"1","generated_at":"2026-11-20T13:22:07.860Z","data_as_of":null,"url":"https://www.findmykol.com/kol/gary-macvicar","json_url":"https://www.findmykol.com/kol/gary-macvicar/profile.json","record_kind":"basic","profile_kind":"clinical","person":{"slug":"gary-macvicar","name":"Gary Macvicar","credential":"MD","specialty":"Hematology / Oncology","specialty_raw":"Hematology & Oncology","therapeutic_area":"Oncology","therapeutic_areas":["Oncology"],"institution":"Illinois CancerCare","institution_url":"https://www.findmykol.com/institution/illinois-cancercare","city":"Peoria","state":"IL","region":{"label":"Midwest","url":"https://www.findmykol.com/region/midwest"}},"identifiers":{"on_file":["npi","orcid","openalex"],"values":"Shown on the profile page to a signed-in account."},"summary":"Gary Macvicar is an Oncology physician affiliated with Illinois CancerCare. OpenAlex indexes 47 publications with 3,735 citations (h-index 20).","overview":null,"focus":{"indications":[],"research_topics":["Oncology"]},"scholarship":{"works_count":47,"cited_by_count":3735,"h_index":20,"latest_activity_year":2026,"source":"works"},"payments":{"company_count":8,"program_years":{"first":2021,"last":null},"rows_total":31,"shown":3,"withheld":28,"rows":[{"payer":"Merck & Co.","program_year":2025,"amount_usd":783908.4,"payment_count":8},{"payer":"Bristol Myers Squibb","program_year":2025,"amount_usd":197743.33,"payment_count":2},{"payer":"Daiichi Sankyo","program_year":2025,"amount_usd":17521.75,"payment_count":7}],"source":"payments"},"prescribing":{"data_year":2023,"areas_total":12,"areas_shown":3,"areas":[{"area":"Cancer & immunology","share_pct":52.2,"classes_total":15,"classes":[{"class":"PD-1 inhibitor","setting":"administered","share_pct":20,"drugs":[{"name":"Pembrolizumab","share_pct":56.3},{"name":"Nivolumab","share_pct":43.7}],"max_beneficiaries":20},{"class":"Nucleoside Metabolic Inhibitor","setting":"administered","share_pct":12.4,"drugs":[{"name":"Azacitidine","share_pct":94.2},{"name":"Fluorouracil","share_pct":3.9},{"name":"Gemcitabine hydrochloride","share_pct":1.9}],"max_beneficiaries":20}]},{"area":"Blood & clotting","share_pct":25.5,"classes_total":4,"classes":[{"class":"Iron, parenteral preparations","setting":"administered","share_pct":21.7,"drugs":[{"name":"Ferric carboxymaltose","share_pct":100}],"max_beneficiaries":26},{"class":"Erythropoiesis-stimulating Agent","setting":"administered","share_pct":3.7,"drugs":[{"name":"Darbepoetin alfa","share_pct":62.8},{"name":"Epoetin alfa","share_pct":37.2}],"max_beneficiaries":14}]},{"area":"Metabolism & gastrointestinal","share_pct":12.5,"classes_total":7,"classes":[{"class":"Substance P/Neurokinin-1 Receptor Antagonist","setting":"administered","share_pct":6.2,"drugs":[{"name":"Aprepitant","share_pct":100}],"max_beneficiaries":25},{"class":"Other antiemetics","setting":"administered","share_pct":2.9,"drugs":[{"name":"Fosaprepitant","share_pct":100}],"max_beneficiaries":11}]}],"care_setting":{"dominant":"office","data_year":2023,"office_pct":100,"facility_pct":0},"source":"medicare"},"publications":{"total":47,"shown":5,"withheld":42,"matched_by":"OpenAlex author record","recent":[{"title":"Therapy for Stage IV Non–Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, 2026.3.0","year":2026,"journal":"Journal of Clinical Oncology","source_url":"https://doi.org/10.1200/jco-25-02822","status":"verified"},{"title":"Therapy for Stage IV Non–Small Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, 2026.3.0","year":2026,"journal":"Journal of Clinical Oncology","source_url":"https://doi.org/10.1200/jco-25-02825","status":"verified"},{"title":"Therapy for Stage IV Non–Small Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, 2026.3.1","year":2026,"journal":"Journal of Clinical Oncology","source_url":"https://doi.org/10.1200/jco-26-00842","status":"verified"},{"title":"Belzutifan plus lenvatinib versus cabozantinib in patients with previously treated advanced renal cell carcinoma (LITESPARK-011): an open-label, randomised, controlled, phase 3 trial","year":2026,"journal":"The Lancet","source_url":"https://doi.org/10.1016/s0140-6736(26)01089-5","status":"verified"},{"title":"Circulating Tumor Cell Count and Overall Survival in Patients With Metastatic Hormone-Sensitive Prostate Cancer","year":2024,"journal":"JAMA Network Open","source_url":"https://doi.org/10.1001/jamanetworkopen.2024.37871","status":"verified"}],"source":"works"},"similar":[{"name":"Michael Veeder","slug":"michael-veeder","institution":"Illinois CancerCare","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/michael-veeder","json_url":"https://www.findmykol.com/kol/michael-veeder/profile.json"},{"name":"Nguyet Le-Lindqwister","slug":"nguyet-le-lindqwister","institution":"Illinois CancerCare","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/nguyet-le-lindqwister","json_url":"https://www.findmykol.com/kol/nguyet-le-lindqwister/profile.json"},{"name":"Francois Geoffroy","slug":"francois-geoffroy","institution":"Illinois CancerCare","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/francois-geoffroy","json_url":"https://www.findmykol.com/kol/francois-geoffroy/profile.json"},{"name":"Paul Fishkin","slug":"paul-fishkin","institution":"Illinois CancerCare","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/paul-fishkin","json_url":"https://www.findmykol.com/kol/paul-fishkin/profile.json"},{"name":"Carl June","slug":"carl-june","institution":"University of Pennsylvania","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/carl-june","json_url":"https://www.findmykol.com/kol/carl-june/profile.json"},{"name":"Stuart Orkin","slug":"stuart-orkin","institution":"Harvard Medical School","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/stuart-orkin","json_url":"https://www.findmykol.com/kol/stuart-orkin/profile.json"},{"name":"Rainer Storb","slug":"rainer-storb","institution":"University of Washington","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/rainer-storb","json_url":"https://www.findmykol.com/kol/rainer-storb/profile.json"},{"name":"Christina Fitzmaurice","slug":"christina-fitzmaurice","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/christina-fitzmaurice","json_url":"https://www.findmykol.com/kol/christina-fitzmaurice/profile.json"}],"coverage":{"note":"A basic directory record. Sections absent here were not yet checked for this person, so absence means not yet looked, never none found.","not_yet_checked":["funding","congress","network","presence","recognition"]},"not_included":{"note":"This document is the public layer: neutral facts cited to their source. Judgments (influence tier, archetype, trajectory commentary) and the itemized rows past each section's public teaser are account features and are not served here or to crawlers.","withheld_rows":{"payments":28,"publications":42}},"sources":{"orcid":{"name":"ORCID","url":"https://orcid.org","provides":"The verified researcher identity that anchors authorship"},"identity":{"name":"NPPES (CMS)","url":"https://npiregistry.cms.hhs.gov","provides":"Identity, specialty and practice location for every U.S. clinician"},"works":{"name":"OpenAlex","url":"https://openalex.org","provides":"Citations, h-index, research topics, most-cited works and congress abstracts"},"payments":{"name":"CMS Open Payments","url":"https://openpaymentsdata.cms.gov","provides":"Industry payments reported to CMS, by company and program year","disclaimer":"Payments are publicly reported to CMS. Their existence does not imply wrongdoing; CMS does not interpret these data.","coverage":"Program years 2021 onward"},"medicare":{"name":"CMS Medicare Part D Prescribers and Part B","url":"https://data.cms.gov/provider-summary-by-type-of-service","provides":"Share of this prescriber's Medicare fee-for-service prescribing by drug class and therapeutic area, classified with WHO ATC and NLM RxClass","disclaimer":"Proportions of the prescriber's own classified prescribing, never patient counts or dollar amounts. Fee-for-service only; CMS publishes about 17 months after the fact and suppresses counts of ten patients or fewer.","data_year":2023}},"methodology_url":"https://www.findmykol.com/about#methodology"}